On June 18, 2025 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, reported presentations at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 21 to 24, 2025, in New Orleans, LA (Press release, Blue Earth Diagnostics, JUN 18, 2025, View Source [SID1234653989]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will unveil new clinical data on its prostate-specific membrane antigen (PSMA)-targeted PET agent and share clinical results that demonstrate potential applications of 18F -fluciclovine in detection of multiple myeloma* and for patients with negative PSMA scans. "Physicians must be equipped with accurate, actionable molecular imaging to guide more informed clinical decisions," said Marco Campione, President and CEO of Blue Earth Diagnostics. "At SNMMI, we look forward to sharing new analyses and scientific information about POSLUMA and Axumin with the molecular imaging community – highlighting our commitment to delivering innovative solutions for improved patient care."

Blue Earth Diagnostics will be presenting seven abstracts around POSLUMA at SNMMI, including an analysis on the prognostic value of baseline 18F-flotufolastat PET bone tumor metrics for the occurrence of severe hematologic toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-I&T.

The Company will also present clinical data around Axumin, highlighting the role of 18F-fluciclovine PET/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET/CT, and potential applications in multiple myeloma.

Blue Earth Diagnostics invites participants at the 2025 SNMMI Annual Meeting to attend the presentations below and to visit the Company at Exhibit Booth 1513.

POSLUMA (flotufolastat F 18)

DATE: Sunday, June 22, 2025
Title: Impact of Baseline 18F-Flotufolastat PET Bone Tumor Volume for Prognosticating Severe Hematologic Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-Labeled PSMA-Targeted Radioligand Therapy
Presenter: Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Oral presentation
Session Time: 5:00 – 5:30 PM CT
Abstract ID.: 251321

DATE: Sunday, June 22, 2025
Title: Prognostic 18F-Flotufolastat PET Parameters for Outcome Assessment of 177Lu-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer
Presenter: Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 1324

DATE: Sunday, June 22, 2025
Title: Follow-up 18F-Flotufolastat PET after negative baseline PET in Patients with Suspected Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy
Presenter: Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 1319

DATE: Sunday, June 22, 2025
Title: 18F-Flotufolastat PET/MRI in Suspicious Prostate Cancer: Correlation with Histopathological Biopsy Results
Presenter: Nicola Gabler, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 1318

DATE: Sunday, June 22, 2025
Title: Real-World Experience on the Diagnostic Efficacy of 18F-Flotufolastat PET/CT in Preoperative N-Staging as Assessed by Readers of Varying Experience Levels
Presenter: Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 1457

DATE: Sunday, June 22, 2025
Title: Impact of PSMA-PET based eligibility criteria using 18F-rhPSMA-7.3 (Flotufolastat) on outcome of Lutetium PSMA radioligand therapy
Presenter: Sonia Grigorascu, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 251150

DATE: Sunday, June 22, 2025
Title: Prognostic Value of 18F-rhPSMA-7.3 (Flotufolastat-F18) PET Using Visual RECIP During Taxane-based Chemotherapy in Prostate Cancer
Presenter: Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 1821

Axumin (fluciclovine F 18) and investigational 18F-fluciclovine
DATE: Sunday, June 22, 2025
Title: 18F-Fluciclovine PET/CT detects more lesions with higher quantitative PET parameters than 18F-FDG PET/CT in multiple myeloma*
Presenter: Liza Lindenberg, M.D., Associate Research Physician, National Cancer Institute, Molecular Imaging, Bethesda, Maryland
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 251312

DATE: Monday, June 23, 2025
Title: Do racial differences impact salvage radiotherapy outcomes for prostate cancer recurrence?
Presenter: Ismaheel Lawal, Senior Research Fellow, Emory University, Department of Radiology and Imaging Sciences, Atlanta, Georgia
Session Type: Poster presentation
Session Time: 12:30 – 1:15 PM CT
Abstract ID.: 251471

DATE: Tuesday, June 24, 2025
Title: Role of 18F-Fluciclovine PET/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET/CT
Presenter: Nadine Mallak, M.D., Associate Professor, Oregon Health and Science University, Department of Diagnostic Radiology Molecular Imaging & Therapy, Body Imaging Director, PET/MRI, Clinical, Portland, Oregon
Session Type: Poster presentation
Session Time: 9:30 – 9:40 AM CT
Abstract ID.: 251638